Last kr132.75 SEK
Change Today -3.50 / -2.57%
Volume 88.2K
MVIRB On Other Exchanges
As of 11:30 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - kr151.00
52 Week Low
11/4/13 - kr77.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

142 Employees
Last Reported Date: 08/21/14

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Announces Sales Results for the Third Quarter of 2014

Medivir AB announced sales results for the third quarter of 2014. For the quarter, net sales of OLYSIO (simeprevir) amounted to $796 million, of which $671 million were sales in the USA.

Medivir AB Initiates Patient Enrolment in Phase II Study Called IMPACT

Medivir AB announced that its partner Janssen recently initiated patient enrolment in a phase II study called IMPACT. This study evaluates the efficacy, safety and pharmacokinetics of the NS3/4A protease inhibitor simeprevir administered once daily in combination with Gilead's nucleotide inhibitor sofosbuvir and Bristol-Myers Squibb's (BMS) NS5A replication complex inhibitor daclatasvir. The study includes treatment-naïve and treatment-experienced patients with hepatitis C genotype 1 and 4 infection and decompensated liver disease. In the phase II, open label IMPACT study, patients will receive the once-daily combination of simeprevir 150 mg, sofosbuvir 400 mg and daclatasvir 60 mg, for 12 weeks. The primary efficacy endpoint in the study is the proportion of patients achieving sustained virologic response 12 weeks after the end of treatment (SVR12). The IMPACT study represents the first phase II study of the combination of simeprevir, sofosbuvir and daclatasvir in a regimen without pegylated interferon and ribavirin.

Medivir AB - Analyst/Investor Day

Medivir AB - Analyst/Investor Day


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr132.75 SEK -3.50

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation MVIRB Industry Range
Price/Earnings 6.4x
Price/Sales 3.9x
Price/Book 2.7x
Price/Cash Flow 6.2x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at